



Food and Drug Administration  
Rockville MD 20857

• APR 21 1999

Re: Amerge™  
Docket No.: 98E-0614

The Honorable Q. Todd Dickinson  
Assistant Secretary of Commerce and  
Commissioner of Patents and Trademarks  
Box Pat. Ext.  
Assistant Commissioner for Patents  
Washington, DC 20231

Dear Commissioner Lehman:

This is in regard to the application for patent term extension for U.S. Patent No. 4,997,841, filed by Glaxo Wellcome, Inc., under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Amerge™, the human drug product claimed by the patent.

The total length of the regulatory review period for Amerge™ is 953 days. Of this time, 519 days occurred during the testing phase and 434 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: July 5, 1995.

FDA has verified the applicant's claim that the date the Investigational New Drug application became effective was on July 5, 1995.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: December 4, 1996.

FDA has verified the applicant's claim that the New Drug Application (NDA) for Amerge™ (NDA 20-763) was initially submitted on December 4, 1996.


3. The date the application was approved: February 10, 1998.

FDA has verified the applicant's claim that NDA 20-763 was approved on February 10, 1998.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Thomas J. McGinnis, R.Ph.  
Deputy Associate Commissioner  
for Health Affairs

cc: David J. Levy, Ph.D.  
GlaxoWellcome, Inc.  
Five Moore Drive  
Research Triangle Park, NC 27709